| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Abul Bashar Mohammad Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Sindhu Doddabokikere Basavarajappa, Bukkasagar Girijashankar Harish, Ameya Joshi and Joseph M Pappachan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph M Pappachan, FRCP, MD, MRCP, Professor, Senior Researcher, Faculty of Science, Manchester Metropolitan University, All Saints Building, Manchester M15 6BH, Greater Manchester, United Kingdom. drpappachan@yahoo.co.in |
| Key Words |
Cotadutide; Type 2 diabetes; Obesity; Diabesity; Glycated hemoglobin; Body weight; Adverse events |
| Core Tip |
Cotadutide, a dual glucagon-like peptide-1/glucagon receptor agonist, effectively lowers glycated hemoglobin and body weight in people with type 2 diabetes and overweight or obesity. A meta-analysis of nine randomized controlled trials reveals modest reductions in blood sugar and weight compared to the placebo, with efficacy similar to that of active comparators. Common side effects include gastrointestinal symptoms (nausea, vomiting, dyspepsia, constipation, decreased appetite) without an excess risk of serious adverse events. Continued use should weigh the benefits of glucose and weight control against the risk of gastrointestinal side effects. Cotadutide’s safety and long-term outcomes require further research; however, it shows promise as a potential therapeutic option for metabolic disorders. |
| Publish Date |
2025-12-15 09:46 |
| Citation |
Kamrul-Hasan ABM, Dutta D, Nagendra L, Basavarajappa SD, Harish BG, Joshi A, Pappachan JM. Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis. World J Diabetes 2025; 16(12): 112830 |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i12/112830.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i12.112830 |
